Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate

  • Intellia Therapeutics Inc NTLA and Regeneron Pharmaceuticals Inc REGN have announced positive interim data from an ongoing Phase 1 study of NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis.
  • Interim results come from the first six patients for the in vivo CRISPR/Cas9 genome editing candidate that reduced serum levels of transthyretin, a key biomarker for the disease, by 87% in patients who received a higher dose. 
  • Mean reductions of 52% among the three patients in the 0.1 mg/kg dose group and 87% among the three patients in the 0.3 mg/kg dose group, including one patient with a 96% reduction.
  • The results bested the standard of care therapy, which typically reduces transthyretin by 80%.
  • NTLA-2001 was generally well-tolerated at both dose levels, with no serious adverse events and no liver findings by day 28. 
  • The candidate is continuing to be evaluated in the dose-escalation portion of the study.
  • After identifying a recommended dose, Intellia expects to begin a single-dose expansion cohort in Part 2 of the Phase 1 trial later this year. 
  • After completing the Phase 1 trial, the company plans to move to pivotal studies for both polyneuropathy and cardiomyopathy manifestations of ATTR amyloidosis.
  • Intellia will host an investor event today at 8:00 a.m. E.T.
  • Price Action: NTLA shares are up 31.1% at $116.49 during the premarket session on the last check Monday, while REGN stock closed at $550.55 on Friday.

Posted In: BriefsGene EditingTransthyretin AmyloidosisBiotechNewsHealth CareContractsFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.